GB1015956A - Process for the preparation of a new medicament - Google Patents

Process for the preparation of a new medicament

Info

Publication number
GB1015956A
GB1015956A GB28500/63A GB2850063A GB1015956A GB 1015956 A GB1015956 A GB 1015956A GB 28500/63 A GB28500/63 A GB 28500/63A GB 2850063 A GB2850063 A GB 2850063A GB 1015956 A GB1015956 A GB 1015956A
Authority
GB
United Kingdom
Prior art keywords
cultures
escherichia coli
hours
culture
autolysate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB28500/63A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eurorga
Original Assignee
Eurorga
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR904533A external-priority patent/FR2427M/en
Application filed by Eurorga filed Critical Eurorga
Publication of GB1015956A publication Critical patent/GB1015956A/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20Milk; Whey; Colostrum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745Bifidobacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747Lactobacilli, e.g. L. acidophilus or L. brevis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1735Mucins, e.g. human intestinal mucin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A medicament useful in the treatment of affections of the gastro-intestinal tract is prepared by culturing separately, on milk containing gastropyloric mucin of the pig, lysine, arginine and histidine, Lactobacillus acidophilus and non-pathogenic Escherichia coli, and either lyophilizing and then mixing the cultures, or first mixing the cultures, keeping the mixture until it is free from histamine, for example for between 12 and 24 hours, and finally lyophilizing. Medicaments containing 50-150 mg. lyophilized culture of Lactobacillus acidophilus and 50-150 mg. of an equal mixture of the lyophilized cultures of two strains of Escherichia coli together with 20-50 mg. of a lyophilized culture of Bifidibacterium bifidus and (unspecified) amounts of streptogenin in the form of an enzymatic autolysate of fish liver or casein and of other factors, may be bound up in a gelatine capsule; when the enzymatic autolysate is a hygroscopic powder, it is presented separately. The Lactobacillus acidophilus is cultivated in a medium consisting of 950 ml. sterilized skimmed milk, 50 ml. of a 1% aqueous solution of pig's gastro pyloric mucin (containing 1-2.5% of solids) which is obtained by subjecting a mixture of red mucous and pyloric antrum of the pig to extraction with an aqueous solution of caustic soda, 0.5 gram each of lysine, arginine and histidine, 5 micrograms of crystalline Vitamin B12 and minor amounts of specified antibiotics. When it has acquired resistance to antibiotics, the ferment is seeded on a similar culture medium containing no antibiotic; before the seeding, the culture medium is sterilized by treating twice at 100 DEG C. with an interval of 24 hours between heating periods. After seeding, the medium is incubated at 41 DEG C. until a homogeneous curdled product is obtained, which takes about 24 hours. The curd may then be directly frozen, for example at -60 DEG C., and lyophilized. Before freezing the lactic acidity may be neutralized to pH 6.5 with trisodium phosphate solution. Non-pathogenic strains of Escherichia coli which acidify lactose-containing media in less than 24 hours, give indole, do not grow on a disclosed medium containing citrate, are free from haemolysins active against red corpuscles and show the greatest resistance to common antibiotics, are preferred. Two different strains of Escherichia coli are separately cultivated in successive mixtures of the above-described culture medium with decreasing amounts of peptone-containing water consisting of 15 grams peptone, 5 grams sodium chloride and 1 gram of lactose per litre.ALSO:A medicament useful in the treatment of affections of the gastro-intestinal tract is prepared by culturing separately, on milk containing gastropyloric mucin of the pig, lysine, arginine and histidine, Lacto bacillus acidophilus and non-pathogenic Escherichia coli, and either lyophilising and then mixing the cultures, of first mixing the cultures, keeping the mixture until it is free from histamine, for example for between 12 and 24 hours, and finally lyophilising. Medicaments containing 50-150 mg. lyophilised culture of Lactobacillus acidophilus and 50-150mg. of an equal mixture of the lyophilised cultures of two strains of Escherichia coli together with 20-50mg. of a lyophilised culture of Bifidibacterium bifidus and (unspecified) amounts of strepogenin in the form of an enzymatic autolysate of fish liver or casein and of other farters may be bound up in a gelatine capsule; when the enzymatic autolysate is hygroscopic powder, it is presented separately. The medicament may be administered to infants and adults in the treatment of gastro-intestinal infections in general, may receiving particular mention, notably gastroenteritis and colitis, and to pigs, immediately they are born, to reduce their rate of mortality.
GB28500/63A 1962-07-19 1963-07-18 Process for the preparation of a new medicament Expired GB1015956A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR904533A FR2427M (en) 1962-07-19 1962-07-19 Bacteriotherapeutic drug, in particular for the treatment of gastrointestinal disorders.
FR939081 1963-06-24

Publications (1)

Publication Number Publication Date
GB1015956A true GB1015956A (en) 1966-01-05

Family

ID=26196723

Family Applications (1)

Application Number Title Priority Date Filing Date
GB28500/63A Expired GB1015956A (en) 1962-07-19 1963-07-18 Process for the preparation of a new medicament

Country Status (4)

Country Link
CH (1) CH423096A (en)
DK (1) DK108015C (en)
GB (1) GB1015956A (en)
LU (1) LU44002A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61280433A (en) * 1985-04-17 1986-12-11 ヴァリオ・リミテッド Acidophilus strain culture, isolation and therapy by same bacteria
US4689226A (en) * 1980-01-11 1987-08-25 Farmos-Yhtyma Oy Process for the production of a bacterial preparation for the prophylaxis of intestinal disturbances in poultry

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS587297B2 (en) * 1976-05-21 1983-02-09 秦 興世 Deodorizers and their manufacturing and storage methods

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4689226A (en) * 1980-01-11 1987-08-25 Farmos-Yhtyma Oy Process for the production of a bacterial preparation for the prophylaxis of intestinal disturbances in poultry
JPS61280433A (en) * 1985-04-17 1986-12-11 ヴァリオ・リミテッド Acidophilus strain culture, isolation and therapy by same bacteria
JPH0648979B2 (en) 1985-04-17 1994-06-29 ヴァリオ・リミテッド Acidophilus strain culture, method for isolating the strain and method for treating the strain with bacteria

Also Published As

Publication number Publication date
DK108015C (en) 1967-07-31
CH423096A (en) 1966-10-31
LU44002A1 (en) 1963-09-03

Similar Documents

Publication Publication Date Title
US3320130A (en) Medicament for colitis, gastroenteritis and enterocolitis
TAMURA Nutriology of bifidobacteria
Hove et al. Lactic acid bacteria and the human gastrointestinal tract
Tamime et al. Microbiological and technological aspects of milks fermented by bifidobacteria
EP0833644B1 (en) Pharmaceutical and diet formulations for the prophylaxis and treatment of gastrointestinal disorders
MacGillivray et al. Use of lactulose to create a preponderance of lactobacilli in the intestine of bottle-fed infants
EP0555618B1 (en) Dietetic and/or pharmaceutical compositions containing lyophilized lactic bacteria
EP1162987B1 (en) Pharmaceutical composition for medical and veterinary use for regenerating intestinal flora in diarrhoea or dyspeptic syndrome
US6156320A (en) Fermented milk nutraceuticals
CN101460181A (en) Prevention and treatment of otitis media with non-pathogenic bacterial strains
Gonzalez et al. Biotherapeutic role of fermented milk
US6358521B1 (en) Fermented milk nutraceuticals
JPH10309178A (en) Antiallergic agent and fermented food containing bifidus bacterium as active component
JP2532911B2 (en) Composition for promoting intestinal colonization of useful bacteria
GB1015956A (en) Process for the preparation of a new medicament
CN107427461B (en) Method for activating lactic acid bacteria
JP3149403B2 (en) Bifidobacterium oligosaccharide utilization improver
US8007783B2 (en) Quality of life for hepatitis C patients with a formulation for administration to the oral mucosa including Lactobacillus delbrueckii subsp. bulgaricus and N-acetyl D-glucosamine
KR102452957B1 (en) Composition for preventing or treating clostridioides difficile infection comprising combination of probiotics
US20050215471A1 (en) Compositions of bacteria and alpha-lactalbumin and uses thereof
JP3587536B2 (en) Calcium reinforcing agent and method for producing the same
JP2018062491A (en) Composition for inhibiting intestinal decrease of lactobacillus lactic acid bacteria counts
JP3390613B2 (en) Bifidus factor activity enhancer / stabilizer
JPS60188060A (en) Live mold powder of bacterium belonging to genus bifidobacterium, having high resistance to acid in stomach, and its preparation
RU2018313C1 (en) Method for producing probiotics for animals and poultry